Baxter International said it weighing the potential impact of the Trump administration's planned tariffs on the medical-products maker's guidance.
Baxter on Monday said it stands by its 2025 goals of 4% to 5% operational sales growth and roughly 16.5% adjusted operating margin, but it noted that the margin guidance doesn't include any impact from the tariffs on imports from Mexico, Canada and China.
The Deerfield, Ill., company said it is working to quantify the expected impact of the tariffs and to identify potential mitigation opportunities, adding that it will provide an update during its fourth-quarter earnings conference call, which it has postponed to Feb. 20 from Feb. 13.
Baxter, which also on Monday announced the departure of Chairman and Chief Executive Jose Almeida, said it expects its fourth-quarter and full-year 2024 results will be in line with the guidance it provided in November.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.